Application of CD138 Immunomagnetic Sorting Myeloma Cells Combined with Fluorescence in Situ Hybridization for Detecting Cytogenetic Abnormalities of Multiple Myeloma
Lu GAO,Qing LIU,Yan SHI,Hui DANG,Qi HE,Zheng WANG,Lin FENG,Ye LI,Xiao-Yan WANG,Na LI,Wen-Jie SONG,Yan-Lin WANG,Shu KONG,Jin LU,Xiao-Jun HUANG,Yue-Yun LAI
DOI: https://doi.org/10.7534/j.issn.1009-2137.2017.03.031
2017-01-01
Abstract:Objective:To investigate the efficiency of direct fluorescence in situ hybridization (D-FISH) versus FISH on CD138 immunomagnetic sorting myeloma cells (MACS-FISH) to detect the cytogenetic abnormalities of multiple myeloma.Methods:Thirty-one patients with multiple myeloma (MM) were detected by D-FISH and MACS-FISH,using 5 probes,including lq21,D13S319,RB1,IgH,P53.The IgH rearrangement positive patients were further examined by 3 IgH rearrangement subtype FISH probes including IgH/FGFR3,IgH/MAF and IgH/CCND1.Results:Metaphase karyotyping revealed cytogenetic abnormalities in 5 cases (16.1％),clonal aberrations were detected in 13 cases (41.9％) by D-FISH,while 25 case(80.6％) with clonal aberrations by MACS-FISH.The results between these 2 FISH methods were significantly different (P =0.042).The detection frequency of clonal aberration by each probes of D-FISH was 22.6％,25.8％,29％,38.7％ and 9.7％ respectively for 1q21 amplification,D13S319 deletion,RB1 deletion,IgH rearrangement and P53 deletion,compared with 48.4％,45.2％,48.4％,67.7％ and 16.1％ respectively by MACS-FISH.The 2 FISH methods were well consistent when the percentage of plasma cells was ≥20％ in bone marrow smears.When the percentage of plasma cells was ＜ 20％ in bone marrow smears,the difference between these 2 methods was very statistically significant (P =0.00).Conclusion:MACS-FISH can obviously improve the detection efficiency of cytogenetic abnormalities in patients with MM.Conventional cytogenetics combined with MACS-FISH is an ideal efficient method to detect the cytogenetic abnormalities in MM patients,and should be applied widely,especially for those patients with the plasma cells ＜ 20％ in bone marrow smears.